TY  - GEN
AU  - Pönisch,Wolfram
AU  - Moll,Barbara
AU  - Bourgeois,Malvina
AU  - Andrea,Marc
AU  - Schliwa,Thomas
AU  - Heyn,Simone
AU  - Schmalfeld,Marion
AU  - Edelmann,Thomas
AU  - Becker,Cornelia
AU  - Hoffmann,Franz Albert
AU  - Schwarzer,Andreas
AU  - Kreibich,Ute
AU  - Egert,Matthias
AU  - Stiegler,Runa
AU  - Krahl,Rainer
AU  - Remane,Yvonne
AU  - Bachmann,Anette
AU  - Lindner,Tom
AU  - Weidhase,Lorenz
AU  - Petros,Sirak
AU  - Fricke,Stefan
AU  - Vucinic,Vladan
AU  - Al Ali,Haifa
AU  - Niederwieser,Dietger
TI  - Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure
SN  - 1432-1335
PY  - 2013///1216
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Bendamustine Hydrochloride
KW  - Boronic Acids
KW  - administration & dosage
KW  - Bortezomib
KW  - Female
KW  - Glomerular Filtration Rate
KW  - Humans
KW  - Immunoglobulin Light Chains
KW  - immunology
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Neoplasm Staging
KW  - Nitrogen Mustard Compounds
KW  - Prednisone
KW  - Pyrazines
KW  - Renal Insufficiency
KW  - Retrospective Studies
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1007/s00432-013-1513-2
ER  -